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Summary. Blinded sample size re-estimation and information monitoring based on blinded
data has been suggested to mitigate risks due to planning uncertainties regarding nui-
sance parameters. Motivated by a randomized controlled trial in pediatric multiple sclero-
sis (MS), a continuous monitoring procedure for overdispersed count data was proposed
recently. However, this procedure assumed constant event rates, an assumption often
not met in practice. Here we extend the procedure to accommodate time trends in the
event rates considering two blinded approaches: (a) the mixture approach modeling the
number of events by a mixture of two negative binomial distributions, and (b) the lump-
ing approach approximating the marginal distribution of the event counts by a negative
binomial distribution. Through simulations the operating characteristics of the proposed
procedures are investigated under decreasing event rates. We find that the type I error
rate is not inflated relevantly by either of the monitoring procedures, with the exception
of strong time dependencies where the procedure assuming constant rates exhibits some
inflation. Furthermore, the procedure accommodating time trends has generally favorable
power properties compared to the procedure based on constant rates which stops often
too late. The proposed method is illustrated by the clinical trial in pediatric MS.
1. Introduction
Misspecification of nuisance parameters in the design of a clinical trial bears the risk
of inconclusive results or wasteful use of resources when the variation in the data is
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larger or smaller than expected, respectively. To mitigate these risks, nuisance pa-
rameter based sample size re-estimation has been suggested and is commonly applied
in clinical trials. Since re-estimation procedures based on blinded or non-comparative
data generally lead to smaller bias and type I error rate inflation than unblinded pro-
cedures, and unblinded procedures bear the risk of compromising the integrity of the
trial, these are preferred in regulatory guidance documents over unblinded approaches
(European Medicines Agency (EMA), 2007; Food and Drug Administration (FDA), 2018;
European Medicines Agency (EMA), 2007).
The variability of the sample size resulting from a nuisance parameter based sam-
ple size re-estimation can be reduced by repeated estimation of the nuisance parame-
ters during the course of the study. The power and expected sample size of designs
with repeated re-estimation are similar to those of designs with a single re-estimation
(Friede and Miller, 2012). If taken to an extreme, repeated sample size re-estimation
results in continuous monitoring with estimation of the nuisance parameters after every
new data point. The trial is stopped once a sufficient level of information, i.e. precision
of treatment effect estimate, is achieved. This is analogous to event-driven trials in which
the trial is stopped once a prespecified number of events is observed.
Blinded continuous monitoring was considered for normally distributed data by Friede and Miller (2012)
and was recently transferred to the setting of recurrent event data by Friede et al. (2018).
Whereas with normally distributed data only the variance needs to be monitored, with
recurrent event data the information depends on the event rates, follow-up times, and
overdispersion parameters, i.e., the between subject-variability. Without knowledge of
the treatment groups the overall event rate can be estimated, which can then be split
into group specific estimates under the assumption of a treatment effect hypothesized
under the planning alternative. In randomized controlled trials, the follow-up times
and the overdispersion parameters are usually assumed to be the same across treatment
groups and therefore can fairly easily be estimated from blinded data pooled from all
treatment groups. It could be shown that the application of such designs lead to shorter
trial durations in comparison to traditional fixed designs while maintaining the power
(Friede, Ha¨ring and Schmidli, 2018). For clinical trials with recurrent event data, con-
tinuous information monitoring differs from a repeated sample size re-estimation in that
continuous information monitoring does not necessary result in a change in sample size.
Depending on the duration of the recruitment period, continuous information monitor-
ing can be materialized in changes in the study duration while keeping the total sample
size as initially planned.
The investigations by Friede et al. were motivated by a randomized controlled trial in
pediatric multiple sclerosis where the annualized relapse rate was the primary endpoint
(Chitnis, Arnold, Banwell et al., 2018). As this was the first large-scale double-blind,
randomized controlled trial in this population, the design had to be based on adult data
resulting in considerable uncertainty. Since the event rates were larger than assumed
in the planning, the trial was stopped early based on results from blinded data looks.
The analysis of this trial confirmed decreasing event rates over follow-up time, a trend
previously also observed in a meta-analysis of adult data by Nicholas et al. (2012). The
procedure by Friede et al. (2018), however, assumes constant event rates. Ignoring time
trends in the event rates potentially may lead to biased estimates of the event rates
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as well as the overdispersion. Given the observed temporal trends in adult data, see
Nicholas et al. (2012), Schneider et al. (2013a) had extended sample size re-estimation
procedures for overdispersed count data, published by Friede and Schmidli (2010b,a), to
account for these. To our knowledge, however, to date no blinded continuous monitoring
procedure of the information for overdispersed count data is available accounting for time
trends in the event rates. With this manuscript we want to close this gap.
The manuscript is organized as follows. In the following section some notation and
underlying concepts are introduced before providing more background on the motivating
clinical trial in pediatric multiple sclerosis in Section 3. In Section 4 blinded monitoring
procedures are proposed and their operating characteristics are explored in a simulation
study described in Section 5. The motivating example is revisited in Section 6. We close
with a brief discussion.
2. Statistical model, hypothesis testing, and information
In this section, we define a non-homogeneous Poisson process with Gamma frailty as
a model for recurrent events with time trends. Moreover, we define the statistical hy-
pothesis of interest as well as an appropriate statistical test. We conclude with defining
information for the introduced statistical model.
Denote Nij(s) the number of events subject j = 1, . . . , ni in group i = T,C has
experienced up to study time s. Study time s is the time since randomization of a
subject, i.e., the exposure time of a subject. We assume that the recurrent events of
each subject stem from a non-homogeneous Poisson process with a log-linear baseline
rate exp(α0 + α1s). Furthermore, proportionality of the rates between the treatment
group and the control group is assumed. Therefore, the rate function for subject j in
group i, conditional on the subject-specific frailty νij , is given by
λij(s)|νij = νijλi(s) = νij exp(α0 + α1s) exp(βxi). (1)
Here, xi is the group indicator which is zero in the control group, xC = 0, and one in
the treatment group, xT = 1. Moreover, the subject-specific frailty νij is modeled as
Gamma distributed, i.e. νij ∼ Γ(1/φ, 1/φ), with the Gamma distribution parameterized
such that νij has an expected value and a variance of 1 and φ, respectively. Hence,
it follows that the number of events Nij(s) conditional on the frailty νij are Poisson
distributed, that is
Nij(s)|νij ∼ Pois (νijΛi(s)) ,
with the cumulative rate function
Λi(s) =
s∫
0
λi(u) du =
1
α1
exp(α0) (exp(α1s)− 1) exp(βxi)
with λi(s) = exp(α0 + α1s) exp(βxi).
The baseline cumulative rate function is denoted and given by ΛC(s) = exp(α0) (exp(α1s)− 1) /α1.
It is important to emphasize that λi(s) and Λi(s) are not only functions of s but also
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functions of α0, α1, and β. However, we do not explicitly mention the parameters α0,
α1, and β in our notation of λi(·) and Λi(·) for the sake of readability. Marginally, the
number of events Nij(s) follows a negative binomial distribution with rate Λi(s) and
shape parameter φ (Lawless, 1987a,b), that is
Nij(s) ∼ NegBin (Λi(s), φ) .
The expected value and the variance of the number of events Nij(s) are Λi(s) and
Λi(s)(1 + φΛi(s)), respectively. Thus, the variance increases in the shape parameter φ.
In this manuscript, we are interested in the superiority of an experimental treatment
over the control. Under the assumption that smaller rates are better, superiority in the
model above is given when the parameter β is smaller than zero. Thus, the question of
superiority of the treatment over control can be written as the statistical testing problem
H0 : β ≥ 0 vs. H1 : β < 0.
To test the null hypothesis H0, we employ a Wald test based on asymptotic maximum
likelihood theory. Therefore, we discuss the maximum likelihood estimation of the pa-
rameters from the model above, (α0, α1, β, φ), and the parameters’ asymptotic properties
at first, followed by an introduction of the Wald test forH0. Let S
(t)
ij be the exposure time
of subject j = 1, . . . , ni in group i = T,C at a calendar time t, and let Nijt = Nij
(
S
(t)
ij
)
by the corresponding number of events. The study times, at which the events of a
subject occurred, are denoted by sij1, sij2, . . .. Then, according to Lawless (1987b), the
likelihood function is given by
L(α0, α1, β, φ|t) =
∏
i=T,C
ni∏
j=1

Nijt∏
k=1
λC (sijk)
ΛC
(
S
(t)
ij
)

× Γ(φ−1 +Nijt)
Γ(φ−1)Nijt!
(
φΛi
(
S
(t)
ij
))Nijt
(
1 + φΛi
(
S
(t)
ij
))Nijt+φ−1 .
(2)
This results in the following log-likelihood function logL(·):
logL(α0, α1, β, φ|t) =
∑
i=T,C
ni∑
j=1
Nijt∑
k=1
[α0 + α1sijk] +
∑
i=T,C
ni∑
j=1
Nijt(log(φ) + xiβ)
+
∑
i=T,C
ni∑
j=1
[
log Γ
(
Nijt + φ
−1
)− log Γ (φ−1)− log (Nijt!)]
−
∑
i=T,C
ni∑
j=1
[
(Nijt + φ
−1) log
(
1 + φΛi
(
S
(t)
ij
))]
. (3)
The maximum likelihood estimators (αˆ0t, αˆ1t, βˆt, φˆt) at calendar time t are calculated
by maximizing the log likelihood function (3). This maximization can be performed by
finding the root of the system of equations ∇ logL(α0, α1, β, φ|t) = 0 using the Newton-
Raphson method. We list the partial derivatives in Appendix A. The maximum like-
lihood estimators (αˆ0t, αˆ1t, βˆt, φˆt) are asymptotically normally distributed in the sense
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that
√
n




αˆ0t
αˆ1t
βˆt
φˆt

−


α0
α1
β
φ



 D−−−→n→∞ N (0,Σ) . (4)
Here, Σ = limn→∞ nI
−1
t with It ∈ R4×4 the Fisher information matrix which is a function
of the sample size, the unknown parameter vector, and the individual exposure times at
calendar time t. For details, we refer to Appendix A. Let c′ =
(
0 0 1 0
)
, we define
the Wald statistic Tt at calendar time t by
Tt =
βˆt√
c′Iˆ−1t c
(5)
with Iˆt the plug-in estimator of the Fisher information matrix obtained by plugging
in the maximum likelihood parameter estimators into the formula of the Fisher infor-
mation matrix. From the asymptotic normality of the maximum likelihood estimator
follows that the Wald statistic Tt is asymptotically standard normally distributed at
the boundary of the parameter space defined by the null hypothesis H0, that is β = 0.
Therefore, the Wald test that rejects H0 when Tt is smaller than the α-quantile zα of a
standard normal distribution is an asymptotic level α test for the null hypothesis H0.
We conclude this section by recapitulating the concept of statistical information. In
general, the information I for a treatment effect β is the reciprocal of the variance of
its estimator βˆ, that is I = 1/Var(βˆ) (Jennison and Turnbull, 2000). The information
I measures the knowledge about the unknown treatment effect β with larger values
corresponding to a smaller uncertainty about the unknown treatment effect. For the
non-homogeneous Poisson process model with Gamma frailty, the information It at
calendar time t is given by
It = 1
Var(βˆt)
=
1
c′I−1t c
.
Analogously to the Fisher information matrix It, the information It is a function of the
sample size, the parameter vector, and the individual exposure times. The information
It increases when the sample size n, the individual exposure times, or the rates increase,
and it decreases when the overdispersion parameter φ increases. Since the information
It is defined through the variance of the parameter estimate, the information is closely
linked to the power of the previously introduced Wald test. For a parameter βH1 located
in the parameter space of the alternative hypothesis H1, the power increases as the
information It increases. Moreover, for a given power P and the significance level α,
the target information Ifix required for the Wald test to achieve a power P for the
parameter βH1 can be determined (Jennison and Turnbull, 2000; Tsiatis, 2006):
Ifix = (z1−α + zP )
2
β2H1
.
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It is worth noting that the target information Ifix only depends on the significance level
α, the target power P , and the assumed effect in the alternative βH1 . When planning a
clinical trial, the sample size n, the study duration, the accrual period, and the maxi-
mum individual exposure time are chosen such that the trial conveys the desired target
information Ifix at the end of the trial for a parameter vector (α0, α1, βH1 , φ). Unless
the exposure times are identical for all subjects at the end of the trial, no closed form
expression for converting the target information into the sample size, study duration,
etc exists (Schneider, Schmidli and Friede, 2013a).
3. Motivating example: Clinical trial in pediatric multiple sclerosis
Multiple sclerosis is a disease of the central nervous system that is in many patients
characterized by periods of disease worsening, so-called relapses, followed by periods
of recovery. Chitnis et al. (2018) published results of a clinical trial (ClinicalTrials.gov
Identifier: NCT01892722) assessing the efficacy and safety of fingolimod versus inter-
feron beta-1a in pediatric multiple sclerosis. The trial included 215 subjects which were
randomized 1:1 between the two treatments. The primary endpoint was the annual-
ized relapse rate determined by a negative binomial regression model of the number of
relapses per subject.
The sample size of the clinical trial in pediatric multiple sclerosis was planned based on
results of the TRANSFORMS clinical trial (ClinicalTrials.gov Identifier: NCT00340834)
which assessed efficacy and safety of fingolimod in adults with relapsing-remitting mul-
tiple sclerosis, because no prior clinical trials in the pediatric population were available.
In detail, the sample size of the clinical trial in pediatric multiple sclerosis was planned
assuming a relative reduction of 50% in the annualized relapse rate from 0.36 for the
interferon beta-1a arm to 0.18 for the fingolimod arm. With a fixed follow-up of two
years per subject, a target power of 80%, a two-sided significance level of 5%, and an
overdispersion parameter of 0.82, a total sample size of 190 subjects was planned. In a
blinded assessment of the accumulated information during the trial, it was determined
that the trial would be overpowered when conducted as initially planned. Based on
this blinded information assessment and in agreement with the regulatory agencies, the
clinical trial design was changed from a fixed duration to a flexible duration and stopped
early.
In the following, we analyze the relapses observed in the clinical trial in pediatric
multiple sclerosis using the non-homogeneous Poisson model with a log-linear time trend
introduced in Section 2. Table 1 lists the parameter estimates for the standard negative
binomial model, which does not account for time trends, and model (1) when applied
to data from the pediatric multiple sclerosis trial. It is important to note that the
primary analysis published by Chitnis et al. (2018) was a negative binomial regression
adjusted for treatment, region, number of relapses in the previous two years before study
enrollment, and pubertal status. For illustrative purposes, we keep the model simple and
do not adjust for covariates.
The estimated relative reduction of the relapse rate is 82% for both models listed
in Table 1 which is in accordance with the results published by Chitnis et al. (2018).
Comparing the models with and without time trend, the cumulative rates after two
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Table 1. Fit of negative binomial model (model without time trend) and model (1)
(model with time trend) for data from the pediatric multiple sclerosis trial. The 95%
confidence intervals of the point estimates are shown in brackets.
Parameter Model without time trend Model with time trend
αˆ0 −0.240 [−0.521, 0.042] −0.066 [−0.431, 0.30]
αˆ1 - −0.236 [−0.553, 0.081]
exp
(
βˆ
)
0.180 [0.106, 0.305] 0.184 [0.109, 0.311]
φˆ 1.31 [0.58, 2.03] 1.26 [0.55, 1.97]
Cumulative rates
ΛˆC(2) 1.57 1.49
ΛˆT (2) 0.283 0.274
years, the estimated effect, and the estimates shape parameter are similar with relative
differences of 5% or less. Moreover, the estimated trend parameter is αˆ1 = −0.23637.
Thus, the estimated relapse rate decreases by 37.67% within two years from 0.936 to
0.584 in the interferon beta-1a and from 0.172 to 0.1 in the fingolimod group. We use
this example in Section 5 to motivate the simulation setting and revisit the example in
Section 6.
4. Blinded continuous information monitoring for recurrent events with time
trends
4.1. Basic setting and notation
In this section we propose a procedure for blinded continuous information monitoring
for the non-homogeneous Poisson model with a Gamma frailty introduced in Section
2. We start by outlining the concept of blinded continuous information monitoring and
introduce notation related to the blinded sample. To begin with, the target information
Ifix for the significance level α, the power P , and the effect βH1 of interest is determined
before the trial. Then, the clinical trial design, that is the sample size, study duration,
accrual period, etc, are determined based on guesstimates for the nuisance parameters
α0, α1, and φ such that the target information is reached at the end of the trial under the
premise of correct nuisance parameter guesstimates. However, instead of conducting the
trial as initially designed, the information It is monitored continuously in the calendar
time t and the trial is stopped at the first point in time at which the monitored informa-
tion exceeds the target information Ifix. After the trial is stopped, the null hypothesis
H0 is tested using the fixed sample Wald test introduced in Section 2. It can occur that
the information at the initially planned end of the trial is smaller than the target infor-
mation. In this case, the trial could be continued beyond its initially planned duration
to obtain the target information Ifix. Naturally, the question about how to continuously
monitor the information arises. Here, we focus on information monitoring procedures
that maintain blinding for reasons outlined in Section 1. From a statistical perspective,
the main challenge in designs with blinded continuous information monitoring is to find
an estimator Iˆt for It without knowing the treatment indicator of subjects. The infor-
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mation It is a function of the nuisance parameters α0, α1, and φ, the treatment effect
β, and the individual exposure times S
(t)
ij . Since data is blinded, β cannot be estimated
and we propose a continuous information monitoring procedure for the planning alter-
native βH1 . Furthermore, the Fisher information matrix It, which is used to calculate
the information It, explicitly depends on the subject-specific treatment group indicator.
Therefore, this section is split into two parts. In Section 4.2 we propose two procedures
for blinded estimation of the nuisance parameters. In Section 4.3 we illustrate how to
estimate the Fisher information matrix, and therefore the information, without knowing
the treatment group indicator.
For the blinded data, the notation introduced in Section 2 is changed by substituting
the index i by (b) and the upper limit of index j is changed from ni to m. In detail, at
calendar time t, subject j = 1, . . . ,m has an exposure time of S
(t)
(b)j and has experienced
N(b)jt events at study times s(b)jk with k = 1, 2, . . .. Let wi = ni/n be the proportion of
patients to be randomized into group i = T,C which is assumed to be known.
4.2. Blinded estimation of nuisance parameters
4.2.1. Mixture approach
In a randomized trial with wi, i = T,C, a subject j = 1, . . . ,m from the blinded sample
has with probability wT been randomized to the treatment group and with probability
wC to the control group. Thus, the cumulative number of events N(b)jt from a subject j
in the blinded sample follows a mixture of two negative binomial distributions, that is
N(b)jt ∼ wT NegBin
(
ΛT (S
(t)
(b)j
), φ
)
+ wC NegBin
(
ΛC(S
(t)
(b)j
), φ
)
. (6)
Modeling the blinded sample through a mixture of two distributions has also been con-
sidered by Asendorf et al. (2017, 2018) in the context of longitudinal count data. Since
we aim to only estimate the nuisance parameters, we replace the cumulative rate func-
tion ΛT (s) in (6) under the assumption of a treatment effect βH1 by ΛC(s) exp(βH1).
From (6) it follows that the log-likelihood of the blinded sample is given by
logLmix(α0, α1, φ|t) (7)
=
m∑
j=1
N(b)jt∑
k=1
[α0 + α1s(b)jk] +
m∑
j=1
N(b)jt log(φ)
+
m∑
j=1
[
log Γ
(
N(b)jt + φ
−1
)− log Γ (φ−1)− log (N(b)jt!)]
−
m∑
j=1
log

 wT exp (βH1)
N(b)jt(
1 + φΛC
(
S
(t)
(b)j
)
exp (βH1)
)N(b)jt+φ−1 + wC(
1 + φΛC
(
S
(t)
(b)j
))N(b)jt+φ−1

 .
(8)
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Then, the maximum likelihood estimator of the nuisance parameters α0, α1, and φ at
calendar time t are defined by(
αˆ0(b)t, αˆ1(b)t, φˆ(b)t
)
:= arg max
α0,α1,φ
logLmix(α0, α1, φ|t). (9)
It is important to emphasize that the mixture approach for blinded estimation of the
nuisance parameters through (9) differs from expectation-maximization (EM) algorithm-
based procedures for blinded parameter estimation in that the EM algorithm-based
procedures also estimate the treatment effect. The appropriateness of EM algorithm-
based procedures has been controversially discussed in the past (Friede and Kieser, 2002;
Waksman, 2007; Cook, Bergeron, Boher and Liu, 2009; Schneider, Schmidli and Friede, 2013b;
Cook, 2013).
4.2.2. Lumping approach
The lumping approach for blinded nuisance parameter estimation in a non-homogeneous
Poisson model with Gamma frailty was proposed by Schneider et al. (2013a), who ex-
tended a previous proposal by Friede and Schmidli (2010b) to dependent event rates.
The idea is to approximate the marginal distribution of the number of events N(b)jt by
a negative binomial distribution, that is
N(b)jt ∼˙ NegBin
(
Λ(b)
(
S
(t)
(b)j
)
, φ
)
, (10)
with the cumulative rate function Λ(b)(·) given by
Λ(b)(s) = wTΛC(s) exp(βH1) + wCΛC(s) =
1
α1
exp(α0) (exp(α1s)− 1) (wT exp(βH1) + wC) .
As the last display shows, the cumulative rate function Λ(b)(·) of the blinded sample
is modeled by a mixture of the cumulative rate function from the treatment arm and
the control arm with the weight of each part equal to the proportion of the sample size
allocated to the respective arm. The blinded estimators for the nuisance parameters
α0, α1, and φ at calendar time t are obtained by maximizing the likelihood function
L(b)(α0, α1, φ|t) of the blinded sample,(
αˆ0(b)t, αˆ1(b)t, φˆ(b)t
)
= arg max
α0,α1,φ
L(b)(α0, α1, φ|t). (11)
The likelihood function L(b)(α0, α1, φ|t) of the blinded sample is the likelihood of a sample
of independent negative binomial distributed random variables with rate parameter and
dispersion parameter as in (10).
The blinded maximum likelihood estimates (11) are not consistent under model (6).
In particular, the parameter estimator φˆ(b) overestimates the dispersion parameter φ as
it accounts for the within-group and the between-group variability in model (10). For the
lumping approach, we modeled the blinded data set by a negative binomial distribution.
Technically, the assumption of a single negative binomial distribution is incorrect as the
blinded sample follows a mixture of two negative binomial distribution as illustrated
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in Section 4.2.1. However, as previous research in the context of blinded sample size
adjustments for negative binomial data has shown, the lumping approach is appropri-
ate for blinded nuisance parameter estimation (Schneider, Schmidli and Friede, 2013a;
Friede and Schmidli, 2010b; Schneider, Schmidli and Friede, 2013b).
4.3. Blinded estimation of information
The entries of the Fisher information matrix It relevant for calculating information It
are sums of subject-specific values fi(S
(t)
ij , α0, α1, β, φ) over j = 1, . . . , ni with either
i = T,C or i = T . Thus, the entries of It have one of the following structures
∑
i=T,C
ni∑
j=1
fi
(
S
(t)
ij , α0, α1, β, φ
)
, (12)
nT∑
j=1
fT
(
S
(t)
Tj , α0, α1, β, φ
)
. (13)
For instance, the entry of It which corresponds to the negative second partial derivative
with respect to α0 is the sum of
fi
(
S
(t)
ij , α0, α1, β, φ
)
=
Λi
(
S
(t)
ij
)
1 + φΛi
(
S
(t)
ij
)
over j = 1, . . . , ni and i = T,C. The summands fi(·) are not identical between the two
groups, that is fT (·) 6= fC(·), under the alternative. Therefore, a blinded estimator of the
Fisher information It is not obtained by simply plugging in the blind estimator for the
parameters α0, α1, and φ from Section 4.2 into the sums. However, when the exposure
times in both treatment groups have the same distribution at a given calendar time t,
the exposure times S
(t)
(b)j
from the blinded sample at calendar time t are distributed as
the exposure times in each treatment group. This results in the following approximation
of the sums (12) and (13) by sums utilizing the exposure times from the blinded sample:
∑
i=T,C
ni∑
j=1
fi
(
S
(t)
ij , α0, α1, β, φ
)
≈
∑
i=T,C
m∑
j=1
wifi
(
S
(t)
(b)j , α0, α1, β, φ
)
, (14)
nT∑
j=1
fT
(
S
(t)
Tj , α0, α1, β, φ
)
≈
m∑
j=1
wT fT
(
S
(t)
(b)j , α0, α1, β, φ
)
. (15)
The sums on the right side of (14) and (15) only use information about the exposure
times that is available in the blinded sample. Therefore, a blinded estimator Iˆ(b)t of the
Fisher information matrix It at calendar time t is obtained in two steps. Firstly, sums
that make up the entries of the Fisher information matrix are rewritten as illustrated in
(14) and (15). Secondly, the nuisance parameters α0, α1, and φ are replaced by blinded
estimates, which we proposed in Section 4.2, and the effect β is replaced by the planning
alternative βH1 .
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We denote the resulting blinded continuous information monitoring procedure by
BCM-Trend–Lump if the nuisance parameters are estimated based on the lumping ap-
proach and by BCM-Trend–Mix if the nuisance parameters are estimated based on the
mixture approach.
5. Simulation study
5.1. Purpose of simulation study and motivation of scenarios
In this section we assess the operating characteristic of the proposed blinded continu-
ous information monitoring procedure. The focus is on two settings. Firstly, when a
sponsor plans a clinical trial, major design aspects are the sample size and the corre-
sponding power of the clinical trial under the assumed effect βH1 . Thus, an important
requirement on blinded continuous information monitoring procedures is that the trial’s
target power P is maintained when the sample size planning assumptions are fulfilled.
We refer to the setting, for which the planning assumptions are fulfilled, as Setting I.
A sponsor’s motivation for conducting a clinical trial with a blinded continuous infor-
mation monitoring procedure is to stop the trial early, that is to reduce the sample
size or the study duration, while maintaining the target power P when the initially
planned trial is overpowered. Therefore, in Setting II, the clinical trials are overpow-
ered due to misspecified planning assumptions. In both settings, we are interested in
multiple performance measures. Firstly, we assess the type I error rate of the blinded
continuous information monitoring procedure since a regulatory requirement of adaptive
designs is to control the type I error rate (Food and Drug Administration (FDA), 2018;
European Medicines Agency (EMA), 2007). Additionally, motivated by regulatory re-
quirements, we evaluate the bias of the treatment effect estimator for designs with
blinded continuous information monitoring. From the sponsor’s perspective, the power
as well as the distributions of the study duration and the sample size of designs with
information monitoring are of interest.
The parameters for the simulation study are motivated by the clinical trial in pediatric
multiple sclerosis published by Chitnis et al. (2018), which was discussed in Section 3. In
detail, we focus on a clinical trial with a planned maximum individual follow-up time of
two years and a recruitment period of two years. The individual follow-up times cannot
be extended beyond the initially planned maximum individual follow-up of two years.
This results in a trial duration of four years for a fixed sample design. The target power
is P = 0.8 for a one-sided significance level of α = 0.025. Motivated by the observed
cumulative rate presented in Section 3, the cumulative rate in the control group after
two years is chosen to be ΛC(2) = 1.5, that is an annualized control rate of 0.75. The
time trend parameter is chosen to be α1 = −0.25,−1,−1.5. A trend of α1 = −1.5 is
included as an extreme case as the rate at two years is less than 0.05. The parameter α0
is chosen such that the cumulative rate is 1.5 after two years. The rate and cumulative
rate functions are illustrated in Figure 1. Under the null hypothesis, the rates are equal
in both groups, that is exp(βH0) = 1 and under the alternative hypothesis, we assume
rate ratios of exp(βH1) = 0.5, 0.7. The shape parameter is φ = 1.25. For Setting I,
which describes the scenario in which the planning assumptions are correct, the sample
size is chosen to be the fixed design sample size nfix required for a power of P . For
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Setting II, the sample size is 1.5nfix to describe an overpowered clinical trial. The fixed
design sample size is nfix = 148 for exp(βH1) = 0.5, and nfix = 510 for exp(βH1) = 0.7.
The trend parameter α1 does not affect the sample size in the fixed design as the fixed
design is planned with an identical follow-up time for each subject. In addition to
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Fig. 1. Rate and cumulative rate for the control group for different time trends.
the blinded continuous information monitoring procedure proposed in Section 4, we
include the blinded continuous information monitoring procedure of Friede et al. (2018)
in our simulation study to assess its robustness concerning time trends in the rate and
to compare its performance to the procedure proposed in Section 4. The monitoring
procedure by Friede et al. (2018) will be summarized in Section 5.2.
5.2. Monitoring procedure by Friede et al.
Friede et al. (2018) proposed an information monitoring procedure for the negative bi-
nomial model with a constant rate µi, i = T,C, and dispersion parameter ϕ, where the
hypotheses of interest are also defined through the rate ratio, that is
H˜0 :
µT
µC
≥ 1 vs. H˜1 : µT
µC
< 1.
Here, we utilize a maximum likelihood test based on the differences of log-rates log(µT )−
log(µC) to test the null hypothesis H˜0. Then, the information at calendar time t is given
by
Jt = 11
ITt
+ 1
ICt
, Iit =
ni∑
j=1
S
(t)
ij µi
1 + ϕS
(t)
ij µi
.
Analogously to the information monitoring procedure proposed in Section 4, to monitor
the information Jt while maintaining the blinding, the parameters µT , µC , and ϕ are
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Table 2. Scenarios considered in the simulation study motivated by
the clinical trial example from Section 3.
Parameter Value
One-sided significance level α 0.025
Target power P 0.8
Maximum individual follow-up [years] 2
Recruitment period [years] 2
Study duration [years] 4
Start time of information monitoring After 0.5 years
Rate ratio exp(βH0) under H0 1
Rate ratio exp(βH1) under H1 0.5, 0.7
Cumulative rate in control group after two years ΛC(2) = 1.5
Time trend α1 -0.25, -1, -1.5
Shape parameter φ 1.25
Sample size allocation (wT , wC) (0.5, 0.5)
Setting I
Planned total sample size nPlan nfix
Setting II
Planned total sample size nPlan 1.5nfix
estimated blinded using either the lumping approach or the mixture approach. For de-
tails on the blinded parameter estimation, we refer to Section 4.1 in Friede et al. (2018).
Denote the blinded estimators for the rate parameters µi, i = T,C, and the dispersion
parameter ϕ by µˆ(b)T , µˆ(b)C , and ϕˆ(b), respectively. Based on the blinded parameter
estimators, the information Jt is estimated through plug-in estimation by plugging in
the following estimators:
Iˆ(b)it = wi
n∑
j=1
S
(t)
(b)j µˆ(b)i
1 + ϕˆ(b)S
(t)
(b)j µˆ(b)i
, i = T,C.
We refer to this procedure by BCM-Const–Mix when the blinded parameter estimation
utilizes the mixture approach and BCM-Const–Lump when the blinded parameter es-
timation utilizes the lumping approach. These procedures test the null hypothesis H˜0
using the standard negative binomial model, that is the model without time trend. This
is in contrast to the BCM-Trend procedures which perform the analysis based on (5)
under the assumption of a time trend.
5.3. Operating characteristics for Setting I
In the following, we present the results of the simulation study for Setting I, that is the
setting in which the planned sample size is equal to the sample size required in the fixed
design to achieve the target power P . The simulation results presented in this section
are based on 50 000 Monte Carlo replications.
Table 3 lists the simulated type I error rate for parameters from Table 2. The sim-
ulated type I error rate for the monitoring procedures generally deviate less than two
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Table 3. Simulated type I error rate for parameters from Table 2 for the statistical test
in the fixed design and the monitoring procedures. Here, exp(βH1) denotes the effect
used for information monitoring. The Monte Carlo error is 0.0007 for a simulated type I
error rate of 0.025.
exp(βH1) α1 Fixed Const–Lump Const–Mix Trend–Lump Trend–Mix
0.5 -0.25 0.0272 0.0276 0.0269 0.0273 0.0267
-1 0.0286 0.0285 0.0292 0.0277 0.0283
-1.5 0.0278 0.0287 0.0286 0.0279 0.0277
0.7 -0.25 0.0250 0.0260 0.0254 0.0259 0.0252
-1 0.0259 0.0267 0.0274 0.0264 0.0263
-1.5 0.0256 0.0260 0.0260 0.0255 0.0253
Table 4. Simulated power for parameters from Table 2 for the statistical test in the fixed
design and the designs with blinded continuous information monitoring procedure. The
Monte Carlo error is 0.0018 for a simulated power of 0.8.
exp(βH1) α1 Fixed Const–Lump Const–Mix Trend–Lump Trend–Mix
0.5 -0.25 0.8095 0.7936 0.7784 0.7923 0.7764
-1 0.8134 0.7996 0.7867 0.7958 0.7809
-1.5 0.8086 0.7970 0.7850 0.7913 0.7749
0.7 -0.25 0.8026 0.7916 0.7873 0.7913 0.7867
-1 0.8040 0.7948 0.7908 0.7910 0.7862
-1.5 0.8056 0.7989 0.7952 0.7932 0.7885
times the Monte Carlo error from the simulated type I error rate of the fixed sample
design. For the scenarios with the larger effect exp(βH1) = 0.5, which corresponds to
the scenarios with the smaller sample size, the type I error rate is inflated for the fixed
sample design and so are the type I error rates of the monitoring procedures. This type I
error rate inflation is due to the finite sample properties of the Wald test. In comparison,
for the scenarios with a larger sample size, that is for the effect size exp(βH1) = 0.7, the
type I error rate is closer to the nominal level for all procedures. The time trend has no
noticeable effect on the type I error rates. The simulated type I error rates of the BCM-
Const procedures are larger than the simulated type I error rates of the BCM-Trend
procedures. However, the difference is not of practical relevance. Whether the difference
between the simulated type I error rates of the BCM-Const and the BCM-Trend proce-
dures is due to the different stopping times, see Table S1 in the supplementary material,
or due to BCM-Const not explicitly accounting for the time trend is not evident from
this simulation study. Table S2 in the supplementary material shows that the continuous
information monitoring does not introduce any noticeable bias in the effect estimates at
the end of the trial: among all scenarios and methods, the maximum simulated bias for
estimators of exp(β) = 1 is smaller than or equal to 0.0015.
Table 4 shows that the blinded information monitoring procedures miss the target
power by up to two percentage points. The monitoring procedures based on the lumping
approach perform better than the procedures based on the mixture approach. This is
due to the overestimation of the dispersion parameter in the lumping approaches which
results in a later stopping times, see Table S4 in the supplementary material. Comparing
the procedures BCM-Const and BCM-Trend for a given method of blinded parameter
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Table 5. Simulated type I error rate for parameters from Table 2 for the statistical test
in the fixed design and the monitoring procedures. Here, exp(βH1) denotes the effect
used for information monitoring. The Monte Carlo error is 0.0007 for a simulated type I
error rate of 0.025.
exp(βH1) α1 Fixed Const–Lump Const–Mix Trend–Lump Trend–Mix
0.5 -0.25 0.0281 0.0281 0.0277 0.0276 0.0276
-1 0.0275 0.0289 0.0287 0.0278 0.0282
-1.5 0.0252 0.0279 0.0287 0.0272 0.0272
0.7 -0.25 0.0252 0.0256 0.0255 0.0250 0.0251
-1 0.0248 0.0263 0.0264 0.0249 0.0256
-1.5 0.0253 0.0276 0.0275 0.0260 0.0263
estimation (lumping or mixture approach), the time trends do not affect the power
noticeably with differences in power of less than 0.01. The differences in power are
associated with differences in the mean stopping time: a smaller power corresponds
to an earlier mean stopping time. Monitoring procedures with a similar power have
similar mean stopping times. The average stopping time of procedures based on the
lumping approach is around 3.5 years which can be up to four months later compared
to procedures based in the mixture approach.
In conclusion, when the planned sample size is identical to the sample size required
in the fixed design to achieve the target power, the monitoring procedures based on the
lumping approach have a power within one percentage point of the target power and
can result in stopping the trial on average around six months earlier. The monitoring
procedures do not result in a reduction of the sample size. For designs with a continuous
monitoring, the mean stopping time under the null hypothesis H0 is smaller than the
mean stopping time under the alternative hypothesisH1. This is due to the larger overall
event rate under the null hypothesis H0.
5.4. Operating characteristics for Setting II
In the following, we study the operating characteristics for the setting in which the
planned sample size is 50% larger that what would be required in the fixed sample
design to achieve the target power. As before, the results are based on 50 000 Monte
Carlo replications. Table 5 lists the simulated type I error rates.
For the scenarios with exp(βH1) = 0.5, the type I error rates in fixed sample designs
and in designs with information monitoring are on average 2.7% and 2.8%, respectively.
The small type I error rate inflation in these scenarios can be explained by the small
sample size. In particular, the final sample size in the designs with information moni-
toring is on average smaller than in the fixed sample design by up to 30%, depending on
the effect size, monitoring procedure, and time trend. For scenarios with a larger effect
size, exp(βH1) = 0.7, the statistical test in the fixed sample design controls the type I
error rate. The simulated type I error rates for the BCM-Trend procedures are within
a range of two times the Monte Carlo error of the simulated type I error rates in the
fixed sample design. For BCM-Const, this only holds for the time trend α1 = −0.25.
The simulated type I error rate for BCM-Const increases in the time trend α1 resulting
in a noticeable type I error rate inflation. The magnitude of the inflation is small with
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Table 6. Simulated power for parameters from Table 2 for the statistical test in the fixed
design and the monitoring procedures. The Monte Carlo error is 0.0018 for a simulated
power of 0.8.
exp(βH1) α1 Fixed Const–Lump Const–Mix Trend–Lump Trend–Mix
0.5 -0.25 0.9333 0.8259 0.8010 0.8222 0.7979
-1 0.9361 0.8389 0.8150 0.8260 0.8006
-1.5 0.9348 0.8420 0.8159 0.8244 0.7964
0.7 -0.25 0.9300 0.8120 0.8048 0.8082 0.8003
-1 0.9295 0.8243 0.8169 0.8097 0.8007
-1.5 0.9307 0.8306 0.8228 0.8080 0.8000
about 0.2 percentage points.
Table 6 shows the simulated power. Table 6 shows that the fixed design is overpow-
ered as anticipated when increasing the required sample size by 50%. The information
monitoring procedures counteract this. However, the BCM-Const monitoring procedures
do not fully mitigate the overpowering and yield a power that is up to four percentage
points larger than the target power. Moreover, the overpowering increases as the time
trend increases for the BCM-Const procedures. Applying the mixing approach for the
blinded parameter estimation in the information monitoring results in a power closer
to the target compared to applying the lumping approach. The monitoring procedures
BCM-Trend, which explicitly account for a time trend, perform better for the scenar-
ios presented in Table 6. In particular, BCM-Trend–Mix achieves the target power for
the considered effect sizes and time trends. BCM-Trend–Lump is overpowered for the
larger effect size. The mean stopping time is about two years or less, see Table S10 in
the supplementary material. Thus, the monitoring procedures result in shorter clinical
trials and also reduce the sample size compared to the fixed sample design.
Summarizing, information monitoring can prevent overpowering of clinical trials with re-
current events and time-depending rates. The information monitoring procedure BCM-
Const proposed by Friede et al. (2018) can result in overpowered and longer running
clinical trial when the event rates are time-dependent. For the considered scenarios,
the monitoring procedures mitigate the overpowering due to a too large sample size by
shortening the trial duration and as such the subjects’ follow-up times.
6. Motivating example revisited
In this section, we revisit the clinical trial in pediatric multiple sclerosis, introduced in
Section 3. We illustrate the four methods for blinded continuous information monitoring
discussed in this manuscript using data from the motivating example (Chitnis, Arnold, Banwell et al., 2018).
Thereto, we estimate for a calendar time during the course of the trial the information
based on the data which was available at said calendar time. For this blinded information
estimation, we assume a treatment effect of exp(βH1) = 0.5, which corresponds to the
planning alternative of the actual trial, and a treatment effect of exp(βH1) = 0.2, which
corresponds to the treatment effect eventually observed (Chitnis, Arnold, Banwell et al., 2018).
Table 7 lists the information level Ifix required for the considered effects exp(βH1) when
a power of P = 80% or P = 90% is targeted.
Figure 2 plots the blinded information estimated for four monitoring procedures
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Table 7. Target information Ifix for a one-sided significance level α = 2.5%.
Treatment effect exp(βH1) Target power P Target information Ifix
0.2 80% 3.03
90% 4.06
0.5 80% 16.34
90% 21.87
versus the calendar time for data from the clinical trial in pediatric multiple sclero-
sis published by Chitnis et al. (2018). Figure 2 shows that for an assumed effect of
exp(β)=0.2 exp(β)=0.5
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Fig. 2. Blinded information estimates versus the calendar time for data from a clinical trial in
pediatric multiple sclerosis under assumed treatment effects of exp(βH1) = 0.2 and exp(βH1) =
0.5.
exp(βH1) = 0.2 the information estimates from the monitoring procedures based on the
lumping approach differ substantially from the information estimates of procedures us-
ing the mixture approach, in particular for dates close the end of the trial. Moreover,
whether a monitoring procedure accounts for the time trend explicitly has no practical
relevance; in other words, the procedures BCM-Trend and BCM-Const are almost identi-
cal for the lumping and the mixture approach, respectively. Since the target information
Ifix for an effect of exp(βH1) = 0.2 is between 3 and 4, depending on the target power, all
four monitoring procedures would have stopped within a couple of months of each other
almost two years before the actual end of the trial. For an effect of exp(βH1) = 0.5, the
monitoring procedures using a mixture approach result in larger information estimates
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than the procedures based on the lumping approach, analogous to an assumed effect of
exp(βH1) = 0.2. The difference between the monitoring procedure with the largest infor-
mation estimate, BCM-Trend–Mixture, and the procedure with the smaller information
estimate, BCM-Const–Lumping, is at most one. For the majority of the trial, this dif-
ference in the estimates has no relevant impact on the potential stopping time as the
information increases by one every one to two months. However, towards the end of the
trial, that is after October 2016 in the considered trial, the information curves become
flat such that a difference of one can have a substantial effect of half a year or more.
None of the considered methods in this section achieve the information Ifix = 16.34
required for target power of P = 80%. It is important to emphasize that during the
conduct of the clinical trial in pediatric multiple sclerosis, the information Ifix = 16.34
was achieved. For the information monitoring during the clinical trial covariates were in-
cluded. Since including covariates reduces the variability, the information is larger when
covariates are included in the blinded parameter estimation. Moreover, the planning
assumption exp(βH1) = 0.5 turned out to be conservative and the information required
to achieve a target power of P = 80% under the observed effect was reached more than
1.5 years before the end of the trial.
7. Discussion
Although the blinded monitoring procedure BCM-Const assuming constant rates previ-
ously proposed by Friede et al. (2018) turned out to be robust to some degree to time
dependencies of the event rates, the procedures accounting for time trends were found
to have more favorable operating characteristics. The proposed monitoring procedures
generally did not inflate the type I error rate beyond levels observed in the fixed sample
designs for the asymptotic Wald test in any practically relevant way and did not bias the
treatment effect estimates in the final analysis. Both properties are important from a
regulatory point of view. If the planning assumptions are correct (Setting 1), application
of the information monitoring can still lead to some considerable time savings. When the
planning assumptions were too conservative (Setting 2), the savings in terms of time and
sample size are of course more pronounced. The differences between the lumping and
the mixture approaches are generally small with a tendency for the lumping approach
to stop trials later resulting in higher power.
Here we used the blinded continuous information monitoring to stop a trial early, if the
information level specified in the planning had be reached. This could be due to higher
event rates or less pronounced overdispersion than assumed, a scenario encountered
in the trial in pediatric MS by Chitnis et al. (2018). If the blinded assessment of the
nuisance parameters reveals that the planning assumptions were too optimistic, then the
initially planned sample size or maximum follow-up time might be increased of course.
We did not explore this here as this was not relevant to our motivating example, but
the combination of blinded continuous monitoring with sample size or group-sequential
design is of practical interest and will be explored by our group in the future.
The analyses of randomized controlled trials are often adjusted for stratification fac-
tors of the randomization or important prognostic variables. Although the procedures
presented here could in principle be expanded to regression models adjusted for covari-
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ates, we did not investigate this any further. However, sample size re-estimation for
covariate adjusted analyses with overdispersed count data has recently been considered
by Zapf et al. (2019). As the motivating example shows, the inclusion of covariates in
the analysis can lead to earlier completion of a trial. Moreover, the procedures presented
here also apply to other time trends than the log-linear trend introduced in (1). For in-
stance, one could apply period functions modeling seasonal trends which are common in
asthma and chronic obstructive pulmonary disease (COPD).
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A. Maximum likelihood theory
For the sake of readability, we omit the index t. Therefore, we denote the exposure time
of subject j receiving in group i at calendar time t by Sij instead of S
(t)
ij , and we denote
the number of event up to time Sij by Nij instead of Nijt.
∂ logL
∂β
=
nT∑
j=1
NTj −
nT∑
j=1
ΛT (STj)(1 + φNTj)
1 + φΛT (STj)
∂ logL
∂α0
=
∑
i=T,C
ni∑
j=1
Nij∑
k=1
1−
∑
i=T,C
ni∑
j=1
Λi(Sij)(1 + φNij)
1 + φΛi(Sij)
∂ logL
∂α1
=
∑
i=T,C
ni∑
j=1
Nij∑
k=1
sijk −
∑
i=T,C
ni∑
j=1
Λi(Sij)
(
1 + φNij
α1(1 + φΛi(Sij))
− (1 + φNij) exp(α1Sij)Sij
α1(1 + φΛi(Sij))(exp(α1Sij)− 1)
)
∂ logL
∂φ
=
∑
i=T,C
ni∑
j=1
Nij
φ
− Ψ
(
Nij + φ
−1
)
φ2
+
Ψ
(
φ−1
)
φ2
− Λi(Sij)(Nij + φ
−1)
1 + φΛi(Sij)
+
log (1 + φΛi(Sij))
φ2
Here, Ψ(x) = Γ′(x)/Γ(x) is the digamma function and Ψ′(·) is the first derivative of the
digamma function. Next, we calculate the second partial derivatives. We start with the
second partial derivatives with respect to φ.
∂2 logL
∂β∂φ
= −
nT∑
j=1
ΛT (STj)(NTj − Λ1(STj))
(1 + φΛT (STj))2
∂2 logL
∂α0∂φ
= −
∑
i=T,C
ni∑
j=1
Λi(Sij)(Nij − Λi(Sij))
(1 + φΛi(Sij))2
∂2 logL
∂α1∂φ
= −
∑
i=T,C
ni∑
j=1
Λi(Sij)
(
Nij − Λi(Sij)
α1(1 + φΛi(Sij))2
− (Nij − Λi(Sij)) exp(α1Sij)Sij
α1(1 + φΛi(Sij))2(exp(α1Sij)− 1)
)
With E[Nij ] = Λi(Sij), it follows that all second partial derivatives with respect to
φ are zero. We continue with the remaining second partial derivatives. We define
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Hij = exp(α0) exp(xiβ1) exp(α1Sij)Sij .
E
[
−∂
2 logL
∂β2
]
=
nT∑
j=1
ΛT (STj)
(1 + φΛT (STj))
E
[
−∂
2 logL
∂α20
]
=
∑
i=T,C
ni∑
j=1
Λi(Sij)
(1 + φΛi(Sij))
E
[
−∂
2 logL
∂β∂α0
]
=
nT∑
j=1
ΛT (STj)
(1 + φΛT (STj))
E
[
−∂
2 logL
∂α0∂α1
]
=
∑
i=T,C
ni∑
j=1
Hij − Λi(Sij)
α1(1 + φΛi(Sij))
E
[
−∂
2 logL
∂β∂α1
]
=
nT∑
j=1
HTj − ΛT (STj)
α1(1 + φΛT (STj))
E
[
−∂
2 logL
∂α21
]
=
∑
i=T,C
ni∑
j=1
α−11 HijSij −
φ
(
H2ij − (Λi(Sij))2
)
+ 2 (Hij − Λi(Sij))
α21(1 + φΛi(Sij))
It follows that the Fisher information matrix I for the parameter vector (α0, α1, β, φ) is
given by
I =
(
I3x3 0
0 a
)
with
I3x3 = E

−


∂2 logL
∂α20
∂2 logL
∂α1∂α0
∂2 logL
∂β∂α0
∂2 logL
∂α1∂α0
∂2 logL
∂α21
∂2 logL
∂β∂α1
∂2 logL
∂β∂α0
∂2 logL
∂β∂α1
∂2 logL
∂β2




and
a = E
[
−∂
2 logL
∂φ2
]
.
To calculate the asymptotic variance of the maximum likelihood estimator for the pa-
rameter vector (α0, α1, β, φ), the inverse Fisher information matrix has to be calculated.
It is given by
I−1 =
(
I−13x3 0
0 1
a
)
.
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The inverse I−13x3 can be calculated using the general formula for the inverse of a 3x3-
matrix. Lastly, we calculate the second derivative with respect to φ:
∂2 logL
∂φ2
=
∑
i=T,C
ni∑
j=1
− Nij
φ2
+ 2
Ψ
(
Nij + φ
−1
)
φ3
+
Ψ′
(
Nij + φ
−1
)
φ4
− 2Ψ
(
φ−1
)
φ3
− Ψ
′
(
φ−1
)
φ4
+
Λi(Sij)φ
−2(1 + φΛi(Sij)) + Λi(Sij)
2(Nij + 1/φ)
(1 + φΛi(Sij))
2
+
Λi(Sij)φ− 2 log(1 + φΛi(Sij))(1 + φΛi(Sij))
φ3(1 + φΛi(Sij))
.
The expected value of the second derivative of the log-likelihood with respect to φ has
no closed form expression.
